GlassScriptPhysician profile
Crystal Cargill
NPI 1407335854
$5,380.68
in general payments reported to CMS, 2019-2025
19 companies · $1,765 in 2025
The $1,765 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $61.30 · 2022: $487 · 2023: $1,515 · 2024: $1,553 · 2025: $1,765.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,682 · Education: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,681.82 |
| Education | $150.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $681.08 | 2022-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Teva Pharmaceuticals USA, INC. | $674.78 | 2022-2025 | Uzedy, Austedo Xr, Austedo |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $655.15 | 2023-2025 | Caplyta |
| Lundbeck LLC | $625.85 | 2022-2025 | Rexulti |
| Neurocrine Biosciences, INC. | $503.02 | 2023-2025 | Ingrezza |
| Abbvie INC. | $489.94 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $370.27 | 2022-2025 | Invega Sustenna, Spravato |
| Axsome Therapeutics, INC. | $333.35 | 2022-2025 | Auvelity |
| Alkermes, INC. | $193.59 | 2023-2025 | Aristada, Lybalvi |
| Takeda Pharmaceuticals U.S.A., INC. | $181.78 | 2022-2025 | Trintellix |
| Vanda Pharmaceuticals INC. | $136.52 | 2022-2025 | Fanapt, Hetlioz |
| Novo Nordisk INC | $111.14 | 2022 | |
| Ironshore Pharmaceuticals INC. | $98.87 | 2022-2024 | Jornay Pm |
| Indivior INC. | $93.89 | 2022-2023 | Perseris |
| Almatica Pharma LLC | $65.94 | 2023-2025 | Loreev Xr, Gralise |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $61.30 | 2021 | |
| Collegium Pharmaceutical, INC. | $36.90 | 2025 | Jornay Pm |
| Corium, LLC | $36.29 | 2022-2023 | Azstarys |
| E.R. Squibb & Sons, L.L.C. | $31.02 | 2024-2025 | Cobenfy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Crystal Cargill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.